IGXT (Intelgenx Technologies) 3-Month Share Buyback Ratio : 0.00% (As of Mar. 2024 )

View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Intelgenx Technologies's current 3-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Intelgenx Technologies's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, Intelgenx Technologies's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelgenx Technologies's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Intelgenx Technologies 3-Month Share Buyback Ratio Calculation

Intelgenx Technologies's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2024 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Mar. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(174.658	-	174.658)	/	174.658
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intelgenx Technologies (OTCPK:IGXT) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Intelgenx Technologies 3-Month Share Buyback Ratio Related Terms

Intelgenx Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2

Website

https://www.intelgenx.com

Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. The company focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer, and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and the United States. The company generates the majority of its revenue from Europe.

Executives

Atai Life Sciences Ag	10 percent owner	KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v.	10 percent owner	524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian	officer: VP, Finance&Admin - Subsidiary	4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham	officer: CEO	15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel	officer: SVP, Corp. Dev&SA - Subsidiary	23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe	10 percent owner, officer: Chief Executive Officer	714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin	officer: CFO	440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny	officer: VP IP,Lgl Affairs - Subsidiary	88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen	officer: VP Business+Corp. Development	4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe	10 percent owner, officer: Corporate Secretary	714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid	officer: Vice President, Operations	4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau	director	2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham	officer: Vice President Manufacturing	102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki	director	118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard	officer: VP Corporate Development	141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4